Most pharmaceutical launch teams believe their research is solid. They run awareness and trial usage studies. They track promotional effectiveness. They audit patient charts. They capture HCP dialogue. By any measure, they look covered. But coverage and connection are two different things—and the gap between them is where most launch underperformance actually lives.
The typical launch research setup involves three to five vendors, each running their own workstream with their own physician panels, their own questionnaires, and their own reports. Each piece of that research is credible on its own. But it was never designed to connect to the others. The result is a research portfolio that creates the illusion of comprehensive insight while leaving the most important questions unanswerable.
The questions that define launch success are not complicated in theory: Is our promotional spend reaching the right doctors? Are those doctors forming positive perceptions of the brand? Are those perceptions translating into prescriptions?
That chain—promotion to awareness to intent to prescribing—is the story every launch team needs to be able to tell. But when your promotional tracking study recruits one set of physicians and your prescribing data comes from a completely different set, you cannot trace it. You have signals everywhere and a coherent story nowhere.
Consider the redundancy dimension alone. In a standard multi-vendor launch research setup, teams are paying to recruit the same physicians multiple times across separate studies—once for ATU, again for promotional tracking, again for chart audits. Beyond the direct cost, the hidden loss is analytic: those separate doctor pools can never be reconciled into the cross-study insights that reveal where launch strategy is actually working and where it isn’t.
Integrated launch tracking addresses fragmentation at the foundation. Rather than running separate studies with separate physicians, a unified approach qualifies the same HCPs across all research modules in a single screener. The same doctors who answer your awareness questions also answer your promotional recall questions and provide the chart data. Now the chain becomes traceable. You can see which doctors were exposed to your promotion, how their perception shifted, and whether their prescribing behavior followed. You are no longer assembling puzzle pieces from different boxes.
With $100M or more invested in launch year alone—representing 30 to 45 percent of a brand’s lifetime commercial spend—the cost of fragmented intelligence is not academic. It is strategic decisions made without the evidence to back them, at exactly the moment when getting the decision right matters most. In crowded therapeutic categories, launches are won or lost in the first six months. Teams that understand what is actually driving their launch performance have a compounding advantage over those who discover the problem in hindsight.
"The 5 Silent Killers of Launch Tracking" details each of these failure modes and the specific research design choices that fix them.